• Contact Us
  • Indexing
  • Submit Manuscript
  • Open Access
  • Journals
  • Home
  • ISSN: 2373-9436
    J Cancer Biol Res 2(1): 1023.
    Submitted: 02 April 2014; Accepted: 24 April 2014; Published: 30 April 2014
    Special Issue entitled:
    Lung Cancer
    Short Communication
    Screening for Lung Cancer
    Fayez Kheir1*, Khaled Eissa1 and Jaime Palomino2
    1Section of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, Louisiana
    2Section of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, Southeast Louisiana Veterans Healthcare System, Louisiana
    *Corresponding author: Fayez Kheir, Section of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, Louisiana
    What is the evidence supporting LDCT screening for lung cancer?
    In recent decades the age-specific mortalities of lung cancer in China have been increased to 9 times in men and women and it become one of the most important public health issues. The high prevalence of smoking in men and more than 70% of nonsmokers, both men and women, could be the biggest contributable factor for those consequences. While the abundant evidence on the health risks of exposure to smoking were available in both international and domestic studies the awareness on the health hazards from tobacco use were quit low in Chinese peoples, even in the health providers. Changes in the contents and the process of the tobacco products in Chinese tobacco product markets were accompanied by increased numbers of the lung cancer cases, increased adenocarcinoma and decreased squamous cell carcinoma of the lung, rather than reducing the overall lung cancer cases. Those suggested that comprehensive smoking-free policy should be implemented in all public places and the process of smoking-free legislation should put forward to create the legal environment and provide effective protection for reducing the incidence of lung cancer. Popularized health education should be also enhanced to raise the public awareness on smoking hazards.

    Lung cancer is the leading cause of cancer related deaths in the United States. The estimated number of lung cancer deaths in 2012 was higher than the total combined number of deaths from breast, prostate and colon cancer. In 2012, according to the published data from the American Cancer Society, a total of 226,160 new cases of lung cancer had been diagnosed with a total death of 160,340 secondary to lung cancer­­­. It was estimated that about 1 person out of 2000 in the US died because of lung cancer in 2012 [1-2].
    Smoking is by far the most important risk factor for lung cancer and at least 85% of lung cancers are attributed to smoking [3]. An estimated 45.3 million people, or 19.3% of all adults (aged 18 years or older), in the United States actively smoke cigarettes [4]. This translates into a significant proportion of the American population at a high risk for lung cancer. Unfortunately, around 75% of newly diagnosed lung cancers are incurable at the time of diagnosis [5].
    Because of the major morbidity and mortality in lung cancer, screening has been a focus of investigation for decades. The US Preventive Services Task Force (USPTF) [6] recommended an annual Low Dose CT (LDCT) scan for persons at high risk for lung cancer based on age and smoking history. A reasonable choice was to recommend screening for persons 55 to 80 years old with a 30 pack-year or more history of smoking who currently smokes or have smoked within the past 15 years. (B recommendation= high certainty of moderate net-benefit or moderate certainty of considerable net-benefit) In addition, patients undergoing screening should be able to undergo curative surgery if needed without serious comorbidities that might limit their life expectancy (Table 1).
    The USPTF emphasized that the highest net benefit for LDCT screening will be in high risk patients for lung cancer in order to avoid unintended consequences such as false-positive results and over diagnosis.
    Table 1 Relation of α-synuclein pathology to non-motor features in PD. LB: Lewy bodies; cLB: cortical Lewy bodies; iLB: incidental Lewy bodies; LN: Lewy neurites.

    Who to screen?

    -Patients between age 55 to 80 -At least 30 pack-year smoking history and actively smoking OR quit within past 15 years - Relatively healthy

    How to screen?

    -Annual low dose CT scans

    Where to screen?

    -In an established screening program to ensure compliance and appropriate follow-up

    What additional input needed?

    -Smoking cessation counseling

    -Shared decision making between physicians and patients discussing potential benefits versus harm

    Table 1 Relation of α-synuclein pathology to non-motor features in PD. LB: Lewy bodies; cLB: cortical Lewy bodies; iLB: incidental Lewy bodies; LN: Lewy neurites.

    ×
    Table 2 Potential Concerns with Low dose CT screening.

    Over diagnosis

    False-positive Results

    Lead-time Bias

    Length-time Bias

    Smoking Cessation

    False Reassurance

    Cost-Effectiveness

    Table 2 Potential Concerns with Low dose CT screening.

    ×
    What are the potential concerns with Lung cancer screening?
    Five randomized controlled trials tested the effectiveness of LDCT in the screening for lung cancer
    1-National Lung Cancer Screening Trial "NLST"
    Funded by the National Cancer Institute, the NLST [7] is the best evidence to date that tested LDCT in lung cancer screening. The NLST enrolled around 50 thousand participants comparing annual LDCT versus single posterior-anterior chest radiograph for three consecutive years. Chest radiograph was chosen as the screening method in the control group rather than conventional care since it was being compared to conventional care in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial [8] at the same time of NLST trial design. In case chest radiography would have shown a benefit, designing the NLST trial with conventional care in the control group would have been less beneficial. Inclusion criteria, was similar to those adopted by the USPTF, which were asymptomatic men and women between the age of 55 and 74, who had a total of 30 pack –year smoking and smoked within the past 15 years. The study was stopped early after a median of 6.5 years of follow up when the reduction in lung cancer mortality achieved 20% (95% CI, 6.8% to 26.7%) in the LDCT group. The lung cancer specific mortality among participants who underwent at least 1 screening test, was 346 deaths out of 26455 participants (1.3%) in the LDCT group compared with 425 deaths out of 26232 participants (1.6%) in the radiography group. The number needed to screen with low-dose CT to prevent one death from lung cancer was 320.
    2-The DANTE (Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essay) was a European study that compared LDCT to conventional care [9]. The study included male patients with a history of 20 pack-year smoking or more with no significant co-morbid conditions between the ages of 60 and 74. Each arm in the study had approximately 1200 patients. The intervention group had 4 annual LDCTs. After a median follow-up of 34 months, the relative risk (RR) of lung cancer mortality among the LDCT group was 0.83 (CI, 0.45 to 1.54). All-cause mortality was equal in both groups at 3 years, with an RR of 0.85 (CI, 0.56 to 1.27).
    3-The DLCT (Danish Lung Cancer Screening Trial) trial compared LDCT to conventional care [10]. This was a single center study that randomized about 2000 participants to each group. The study included men and women aged between 50 to 70 years, who were current or former smokers with at least 20 pack years of smoking history. Former smokers should have quit after the age of 50 years and have been abstinent for <10 years. Participants had to be able to climb two flights of stairs without pausing. Lung function was measured by spirometry and forced expiratory volume in the first second had to be at least 30% of predicted. Participants with nodules with diameters larger than 15 mm or rapidly growing were referred for diagnostic workup. After a median follow-up of 4.8 years, the RR for lung cancer mortality all-cause mortality was 1.37 (CI, 0.63 to 2.97) and 1.46 (CI, 0.99 to 2.15) in the LDCT group compared to the control group.
    4-The MILD (Multicentric Italian Lung Detection) study was another single-center trial that randomized about 4000 participants to three groups comparing annual or biennial LDCT versus no screening [11]. The trial included men and women aged 49 years or older with a history of 20 pack-year smoking or more that smoked within the past 10 years. There was no difference in cancer related mortality or total mortality between across the groups. The lung cancer related mortality and the total mortality hazard ratio was 1.52 (95% CI 0.63–3.65) and 1.39 (95% CI 0.83–2.34) when both LDCT arms were compared to the control group. The follow up periods reported were different between groups (45 months for the combined LDCT group vs. 56 months for the control group).
    5- The NELSON (Nederlands Leuvens Longkanker Screenings Onderzoek) trial is the largest ongoing European lung cancer screening study using LDCT. A total of 15,822 participants were enrolled and randomized to either screening with LDCT (7,915) at baseline, 1, 3 and 5.5 years later or no screening (7,907). Inclusion criteria were age 50 – 75 years, smoking history of 15 or more cigarettes per day for 25 years or 10 or more cigarettes for 30 years and either current smokers or history of having quit less than 10 years ago. Patients are expected to have a follow up for 10 years. In this study, CT images are analyzed by semi automated volume measurements software. Final results are not published yet, but preliminary data has shown a favorable lung cancer stage distribution at diagnosis (70.8% stage I) [12].
    Risks of LDCT
    1-Radiation Exposure: The risk of cancer induced radiation is currently estimated based on models mostly developed from atomic bombing survivors and many studies of medical imaging exposure.
    The estimated radiation dose for LDCT per-exam is 1.4 mSv, as reported in the NSLT. However, there are Variations between different centers. Doses at this range is less than half of annual background exposure from living in the United States and less than one quarter of a diagnostic CT scan dose which is about 8mSv. It is estimated that the NLST participants received approximately 8 mSv per participant over 3 years, including both screening and diagnostic examinations (averaged over the entire screened population). Using these information and cancer related radiation models, Beach et al, estimated that one cancer death may be caused by radiation from imaging per 2500 persons screened. As the number needed to screen with LDCT to prevent 1 lung cancer related death is 320, the benefits of LDCT screening outweigh the risk of cancer induced by radiation [13,14].
    2-Complications of Diagnostic Procedures: In the NLST trial [7], around 2.5 % of the positive test results required additional diagnostic procedure. The rate of complication from any further intervention was around 0.36% and rate of mortality was 0.035% (<0.15) within 60 days after any invasive procedure.
    What are the potential concerns with Lung cancer screening?
    • Over diagnosis in screened population (Table 1)
    It is a bias that occurs during a screening test where indolent cancer is identified but probably will never affect the patient's overall healthcare or long-term prognosis. Previous chest radiography screening studies identified an over diagnosis rate of about 25% [14], whereas the Mayo screening study [15] showed that around 27% of all cancer detected have a doubling time of >400 days suggesting over diagnosis bias. In the NLST, the probability that any type of lung cancer to be an over diagnosis is 18.5% in the LDCT arm during the 7 year follow up period [16]. Therefore, patients might undergo unnecessary diagnostic interventions and treatment leading to increased cost, morbidity and sometimes mortality in an indolent cancer that might never cause clinical disease.
    • False Positive Scans
    It is defined as having at least one CT scan with non-calcified nodule that was found later to be non-malignant. High false positive rates were commonly found during screening for lung cancer. In the NLST, around 24.2% of the subjects had at least one positive CT scan during screening and 96.4% of those were false positive [7]. Most subjects were subsequently followed by additional CT scan but few underwent unnecessary diagnostic testing.
    • Lead-Time Bias
    It refers to early detection of lung cancer before clinical symptoms develop but without changing the life expectancy of patients.
    • Length-Time Bias
    It refers to the ability to detect indolent tumors during annual LDCT screening much more likely than aggressive rapidly –growing tumors as they move slowly from indolent stage to clinical symptoms.
    • Smoking Cessation
    One major concern in patients that will undergo annual LDCT screening is smoking behavior. Unfortunately, two major studies did not show any difference in smoking cessation rates between patients assigned to LDCT versus no LDCT [17,18]. Physicians should educate patients about smoking cessation and offer medical as well as psychological therapy if needed.
    • False Reassurance
    The sensitivity for LDCT to detect lung cancer is between 80 to 100%, with a false negative rate that ranges between 0 to 20% [19-22].Therefore, a formal discussion between physician and patient should be done before committing any patient to long term screening.
    • Cost Effectiveness
    The number needed to screen in the NLST to save one life is 320 patients [7]. This compares favorably well with screening modalities such as colonoscopy and mammography. However, the actual quality-adjusted life-year gained for LDCT screening might vary from as low as 19,000$ to more than 2,000,000$ depending on patient's smoking status (lower cost for current smokers compared to higher costs for former smokers), screening adherence and diagnostic procedures [23-25].
    Establishing a Screening Clinic
    There is no doubt that once LDCT screening is widely endorsed the number of patients with lung nodules will increase dramatically. Therefore, a multidisciplinary team consisting of pulmonologist with special interest in lung cancer, radiologist, thoracic surgeon, nurse and a social worker are needed to initiate screening in high risk patients as well as follow up patients appropriately afterwards. Furthermore, it is recommended that only patients who meet USPTF criteria should undergo screening. A formal discussion between the physician and patient about the benefits, risks and potential uncertainties for LDCT screening should be held before committing anyone to a screening program. In addition, all current smokers should be counseled about smoking and offered therapy or be enrolled in a special program for smoking cessation.
    Future Directions
    An accurate and practical model that can predict the probability that a lung nodule is malignant and that can be used to guide clinical decision making will reduce costs and the risk of morbidity in screening programs. Some models based on patient and nodule characteristics have been developed with encouraging results [26]. Recent advances in genomics, epigenomics, proteomics and metabolomics, have identified potential biomarkers in the blood, urine, exhaled breath condensate, bronchial specimens, saliva and sputum that may help to select the most-at risk population for lung cancer, potentially reducing unnecessary work ups in low risk patients [27].
    Summary and Conclusion
    LDCT screening reduces mortality in a high risk population as defined by the NLST. Screening through a dedicated clinic or specialized program will probably maximize cost benefit, reduce unnecessary interventions and assure adequate follow-up leading to overall better patients' welfare. Smoking cessation should be an essential part of a lung cancer screening program.
    References
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer. J Clin. 2012; 62: 10-29.
    2. Boiselle P. Computed Tomography Screening for Lung Cancer. JAMA, 2013; 309: 1163-1170.
    3. Paoletti L, Jardin B, Carpenter MJ, Cummings KM, Silvestri GA. Current status of tobacco policy and control. J Thorac Imaging. 2012; 27: 213-219.
    4. Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 61: 889-894.
    5. Jett JR. Current treatment of unresectable lung cancer. Mayo Clin Proc.1993; 68: 603-611.
    6. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157: 120-134.
    7. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
    8. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011; 306: 1865-1873.
    9. Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009; 180: 445-453.
    10. Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax. 2012; 67: 296-301.
    11. Pastorino U, Rossi M, Rosato V, Marchianò A, Sverzellati N, Morosi C, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012; 21: 308-315.
    12. Horeweg N, van der Aalst CM, Thunnissen E, Nackaerts K, Weenink C, Groen HJ, et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med. 2013; 187: 848-854.
    13. Boiselle PM. Computed tomography screening for lung cancer. JAMA. 2013; 309: 1163-1170.
    14. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012; 307: 2418-2429.
    15. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Tazelaar HD, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology. 2007; 242: 555-562.
    16. Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC,et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014; 174: 269-274.
    17. Ashraf H, Tønnesen P, Holst Pedersen J, Dirksen A, Thorsen H, Døssing M. Effect of CT screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial (DLCST). Thorax. 2009; 64: 388-392.
    18. van der Aalst CM, van den Bergh KA, Willemsen MC, de Koning HJ, van Klaveren RJ. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax. 2010; 65: 600-605.
    19. Menezes RJ, Roberts HC, Paul NS, McGregor M, Chung TB, Patsios D, et al. Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience. Lung Cancer. 2010; 67: 177-183.
    20. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, et al. CT screening for lung cancer: five-year prospective experience. Radiology. 2005; 235: 259-265.
    21. Toyoda Y, Nakayama T, Kusunoki Y, Iso H, Suzuki T. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. Br J Cancer. 2008; 98: 1602-1607.
    22. Veronesi G, Bellomi M, Scanagatta P, Preda L, Rampinelli C, Guarize J, et al. Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program. J Thorac Cardiovasc Surg. 2008; 136: 611-617.
    23. Wisnivesky JP, Mushlin AI, Sicherman N, Henschke C. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. Chest. 2003; 124: 614-621.
    24. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003; 289: 313-322.
    25. Chirikos TN, Hazelton T, Tockman M, Clark R. Screening for lung cancer with CT: a preliminary cost-effectiveness analysis. Chest. 2002; 121: 1507-1514.
    26. McWilliams A, Tammemagi M, Mayo J, Roberts H, Liu G, Soghrati K, et al. Probability of Cancer in Pulmonary Nodules Detected on First Screening CT. N Engl J Med. 2013; 369: 910-919.
    27. Hassanein M, Callison J, Callaway-Lane C, Aldrich M, Grogan E, Massion P. The State of Molecular Biomarkers for the Early Detection of Lung Cancer. Cancer Prev Res. 2012; 5: 992-1006.
    Cite this article: Kheir F, Eissa K, Palomino J (2014) Screening for Lung Cancer. J Cancer Biol Res 2(1): 1023.
  • Current Issue Highlights
  • BRAT1 was originally identified as a BRCA1 interacting protein [1], however, subsequent studies showed that it also binds to ATM, DNA-PK, and SMC1,
    Readmore...

    Mechanisms of detecting and repairing damaged DNA are conserved and controlled through the DNA damage response (DDR).
    Readmore...

    JSciMed Central Peer-reviewed Open Access Journals
    10120 S Eastern Ave, Henderson,
    Nevada 89052, USA
    Tel: (702)-751-7806
    Toll free number: 1-800-762-9856
    Fax: (844)-572-4633 (844-JSCIMED)
    E-mail: cancerbiology@jscimedcentral.com
    1455 Frazee Road, Suite 570
    San Diego, California 92108, USA
    Tel: (619)-373-8720
    Toll free number: 1-800-762-9856
    Fax: (844)-572-4633 (844-JSCIMED)
    E-mail: cancerbiology@jscimedcentral.com
    About      |      Journals      |      Open Access      |      Special Issue Proposals      |      Guidelines      |      Submit Manuscript      |      Contacts
    Copyright © 2016 JSciMed Central All Rights Reserved
    Creative Commons Licence Open Access Publication by JSciMed Central is licensed under a Creative Commons Attribution 4.0 International License.
    Based on a work at https://jscimedcentral.com/. Permissions beyond the scope of this license may be available at https://creativecommons.org/.